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Introduction
Multiple sclerosis (MS) affects more women than 
men,1 and at the time of diagnosis many women 
are of child-bearing age. Patients, partners and 
healthcare professionals need to consider the ben-
efits and risks of continuing MS treatment when 
planning a pregnancy and in the case of unplanned 
pregnancy. Documentation of fetal and maternal 
risks of fingolimod exposure periconceptionally 
and in early pregnancy will help inform pregnancy 
management choices.
Fingolimod (FTY720; Gilenya®) is a sphingo-
sine 1-phosphate (S1P) receptor modulator 
approved for the treatment of relapsing MS. 
During embryonic development, S1P1, S1P2 and 
S1P3 receptors, which are expressed within the 
endothelial cells and vascular smooth muscle 
cells, regulate vascular development and its func-
tion. S1P1 signaling plays an important role dur-
ing embryonic neurogenesis and subsequent 
development of nervous system.2,3 Preclinical 
studies in rabbits and rats have demonstrated 
reproductive toxicity of fingolimod, including 
fetal loss and congenital defects (notably persis-
tent truncus arteriosus and ventricular septal 
defect).4 At the time of the launch of fingolimod, 
there were sparse data available on the safety of 
fingolimod in pregnant women. After discontin-
uation of fingolimod, it takes approximately 
2 months to eliminate the drug from the body;5 
hence, the label recommends that all women of 
child-bearing potential should use effective con-
traception during and for 2 months following 
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Background and Methods: Limited data are available on the safety of fingolimod in 
pregnant women. We estimated the risk of adverse pregnancy outcomes in women with 
multiple sclerosis (MS) exposed to fingolimod either shortly before or during pregnancy 
in prospectively collected cases from clinical trials, observational studies, surveillance 
programs, and spontaneous reports.
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significantly higher than those in the general population and the unexposed MS population. 
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defects was identified.
Conclusions: These data can help inform healthcare professionals and women with MS 
exposed to fingolimod during conception.
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discontinuation of fingolimod treatment.5 
Additional prospective data on pregnancy out-
come are necessary to provide more reliable 
information for patients, their families, and 
prescribers.
The objective of this report is to describe the esti-
mated risk of adverse pregnancy outcome follow-
ing fingolimod exposure, based on all data 
captured in the Novartis safety database (NSDB) 
to date from a variety of sources.
Methods
Data sources and definition of cases
The NSDB includes pregnancy outcomes from 
the following data sources with a database that 
was locked at the end of February 2017: (a) the 
Gilenya® Pregnancy Exposure Registry (referred 
to as the Registry), launched in May 2011 to pro-
spectively collect safety data on maternal, fetal 
and infant outcomes associated with fingolimod 
exposure during pregnancy and up to 8 weeks 
before the last menstrual period (LMP); (b) 
PRegnancy outcomes Intensive Monitoring 
(PRIM), which was instituted on the 1 March 
2014 to collect additional data from pregnant 
patients prospectively reported to Novartis who 
were not enrolled in the Registry; (c) other preg-
nancy cases reported to Novartis outside of these 
programs from a variety of sources including clin-
ical trials, observational studies, surveillance pro-
grams, and spontaneous reports.
For the Registry, cases were considered prospec-
tive if at the time of enrollment, no prenatal test-
ing had been done and pregnancy outcome was 
not known. Cases were considered retrospective 
if prenatal tests had been performed at enroll-
ment, while the patient is still pregnant, regard-
less of their results. For PRIM and NSDB, 
prospective cases included those for which pre-
natal testing was performed and in which the 
results were either normal or not known. When 
analyzed as part of the NSDB, the NSDB defini-
tion of ‘prospective cases’ was applied to Registry 
cases. Prenatal testing was conducted according 
to the routine medical practice in the corre-
sponding countries. Tests included but were not 
limited to targeted ultrasound, amniocentesis, 
nuchal translucency scan or chorionic villus 
sampling.
Data reported here are obtained from prospective 
cases unless otherwise specified.
The protocol for the Registry was approved by 
the local Institutional Review Boards in all the 
countries where the Registry was launched and 
written informed consent was obtained from all 
the patients.
Pregnancy outcomes from the above sources are 
put into context with MS patients who were not 
previously exposed to any disease-modifying ther-
apy (unexposed MS patients) and with the gen-
eral population.
Pregnancy outcomes
The primary outcome measure was the preva-
lence of major congenital malformations, defined 
as any structural defects with recognized surgical, 
medical, or cosmetic importance as per the 
European Surveillance of Congenital Anomalies 
(EUROCAT) guidelines, while anomalies were 
qualified as minor if they were of no serious medi-
cal or cosmetic consequence to the child. Other 
outcome measures included miscarriages, elective 
abortions, stillbirths, neonatal deaths (counted in 
live births), and term and preterm live births with 
or without congenital malformations.
Congenital malformations were judged by exter-
nal adjudicators (qualified pediatrician, clinical 
geneticist, teratologist, pediatric neurologist, 
nephrologist, toxicologist, or clinical pharma-
cologist), according to the EUROCAT or 
other guidelines.6 In cases of discrepancy, cases 
were classified as the more severe of the two 
adjudications.
Statistical analysis
Descriptive statistics, including mean ± standard 
deviation, median (range) and proportions [95% 
confidence interval (CI)] were used to describe 
the data. CIs for the proportions of pregnancies 
were calculated using the Clopper–Pearson 
method. The prevalence of major congenital mal-
formations in live births and in live births, still-
births and terminations of pregnancy due to fetal 
anomaly (TOPFA) cases was reported for the 
Registry, PRIM and NSDB, and the prevalence 
of major cardiac malformations was reported for 
the NSDB.
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Results
By the end of February 2017, a total of 1246 pro-
spectively collected pregnancies with 1255 infants 
were recorded in the NSDB (Figure 1).
Baseline characteristics
Maternal baseline demographics and MS disease 
characteristics are presented for the Registry and 
PRIM cases (Table 1). Availability of this infor-
mation for other cases in the NSDB was limited. 
The mean age at LMP was comparable between 
the Registry and PRIM (31.7 versus 31.6 years). 
In both data sources, more than 75% of the 
patients were exposed to fingolimod either 
within 8 weeks before LMP or during the first 
trimester.
Pregnancy outcome
The prevalence of major congenital malforma-
tions among live births was 4.0% in the Registry, 
2.7% in PRIM, and 3.9% overall in NSDB. The 
prevalence of major congenital malformations 
(excluding chromosomal anomalies) among live 
births, stillbirths and cases with TOPFA was 
5.3% in the Registry, 3.2% in PRIM and 4.5% 
overall in the NSDB (Table 2). In the NSDB, the 
prevalence of major cardiac malformations was 
1.5% in live births and 1.6% in live births, still-
births and TOPFA cases.
All pregnancy outcomes observed separately in 
the Registry and PRIM as well as for all NSDB 
cases are presented in Table 3. Miscarriages were 
reported in 6.6%, 14.7% and 13.5% of fetuses in 
the Registry, PRIM, and NSDB, respectively. 
Elective terminations were reported in 9.9%, 
19.8% and 17.4% of fetuses, respectively. No 
specific pattern of malformations was identified 
among the observed cases. A description of major, 
minor malformations and anomalies that were 
not otherwise specified (NOS), observed in pro-
spective cases, is provided in Table 4. Cardiac 
anomalies were reported in 10 infants, musculo-
skeletal anomalies in 9 infants and renal anoma-
lies in 7 infants (Table 4).
Of the 58 pregnancies enrolled retrospectively in 
the Registry, the outcome was known for 53 
cases: 45 full-term live births including one 
infant with congenital malformation and eight 
Figure 1. Disposition of cases collected in the Novartis safety database from various data sources.
Therapeutic Advances in Neurological Disorders 11
4 journals.sagepub.com/home/tan
Table 1. Baseline characteristics and pregnancy information at enrollment/reporting.
Characteristic Gilenya® Registry
n = 113
PRIM
n = 674
Age at LMP (years), mean ± SD 31.7 ± 4.6 31.6 ± 5.6a
Gestational age at enrollment/reporting (days), median (range) 66.0 (−48.0 to 271.0)b 53c (−60 to 2252)b
Age at MS diagnosis (years), mean ± SD 24.4 ± 5.6 NA
Duration of MS since diagnosis at enrollment (years), mean ± SD  7.4 ± 4.5 NA
Timing of exposure in pregnancyd, n (%)  
 Peri-LMP (within 8 weeks before LMP) 97 (85.8) 26 (7.9)
 First trimester 97 (85.8) 221 (67.4)
 After first trimester 5 (4.4) 14 (4.3)
 During all pregnancy 1 (0.9) –
 Exact timing of exposure unknown 9 (8.0) 67 (20.4)
aThis is based on 88% of PRIM cases.
bExtreme range in the Registry is attributed to a case with an informed consent date on 20 January 2015 and an estimated delivery date on 14 
December 2015, resulting in a negative gestational age at enrollment and another case which did not report any prenatal test and therefore is 
considered prospective; in PRIM outliers may be due to technical issues with how manufacturer’s received date is determined.
cThis is based on 75.9% of PRIM cases with known outcomes that provided data.
dIn PRIM, patients are categorised as per fingolimod discontinuation, therefore the categories are mutually exclusive; in the Registry, patients are 
included in all categories in which fingolimod was taken.
LMP, last menstrual period; MS, multiple sclerosis; N, number of cases enrolled; NA, not available; PRIM, PRegnancy outcomes Intensive 
Monitoring; SD, standard deviation.
Table 2. Prevalence of major congenital malformations among the prospective cases with known outcomes.
Population Registry PRIM NSDB
Cases/
denominator
Prevalence, %
(95% CI)
Cases/
denominator
Prevalence, %
(95% CI)
Cases/
denominator
Prevalence, %
(95% CI)
Live birthsa 3/75 4.0
(0.8; 11.2)
6/219 2.7
(1.0; 5.9)
19/482c 3.9
(2.4; 6.1)
Live births + stillbirths 
+ TOPFAb (excluding 
chromosomal anomaly)
4/76d 5.3
(1.5; 12.9)
7/222 3.2
(1.3; 6.4)
22/490 4.5
(2.8–6.7)
Live births + stillbirths 
+ TOPFAb (including 
chromosomal anomaly)
4/76d 5.3
(1.5; 12.9)
9/222 4.1
(1.9; 7.6)
25/490 5.1
(3.3; 7.4)
aNumber of term and preterm live births (including neonatal deaths) with major congenital malformations as the numerator; all term and preterm 
live births (including neonatal deaths) as the denominator. There were no major chromosomal anomalies reported in live births.
bNumber of cases with major congenital malformations among all term and preterm live births (including neonatal deaths) plus stillbirths plus 
TOPFA as the numerator; number of all term and preterm live births (including neonatal deaths) plus stillbirths plus TOPFA as the denominator.
c482 infants (476 pregnancies) are considered for the prevalence calculation following the exclusion of 12 pregnancies for which the specific timing 
of exposure was not confirmed.
dIn the Registry, no chromosomal abnormality was reported.
CI, confidence interval; NSDB, Novartis safety database; PRIM, PRegnancy outcomes Intensive Monitoring; TOPFA, terminations of pregnancy due 
to fetal anomaly.
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Table 3. All pregnancy outcomes among prospective cases with known outcomes.
Outcome, n (%) Registry
n = 113
PRIM
n = 674
(681 infants)
NSDBa
n = 1246
(1255 infants)
Number of pregnancies with known outcome, n 91 328
(334 infants*)
717
(725 infants*)
Ectopic pregnancies 1 (1.1) 0 (0.0) 4 (0.6)
Miscarriages 6 (6.6) 49 (14.7) 98 (13.5)
Elective termination with congenital malformationb 1 (1.1) 3 (0.9) 6 (0.8)
Elective termination without congenital malformation or 
unknown
8 (8.8) 63 (18.9) 120 (16.6)
Stillbirth with congenital malformationb 0 (0.0) 0 (0.0) 1 (0.1)
Stillbirth without congenital malformation 0 (0.0) 0 (0.0) 2 (0.3)
Live births  
 Live births with congenital malformations  
   Full-term/post-term live birth with congenital 
malformationb
7 (7.7) 7 (2.1) 23 (3.2)
  Preterm live birth with congenital malformationb 0 (0.0) 1 (0.3) 5 (0.7)
  Neonatal death with congenital malformationb 0 (0.0) 0 (0.0) 0 (0.0)
 Live births without congenital malformations  
   Full-term/post-term live birth without congenital 
malformation
60 (65.9) 193 (57.8) 421 (58.0)
  Preterm live birth without congenital malformation 7 (7.7) 15 (4.5) 40 (5.5)
  Neonatal death without congenital malformation 1 (1.1) 3 (0.9) 5 (0.7)
Data are presented as n (%), unless specified otherwise.
*Number of infants is used as the denominator to calculate the percentages. In the Registry, this is equal to the number of 
pregnancies.
aFor the NSDB, infants may appear in two categories (such as live birth with subsequent neonatal death); therefore, the 
sum will be more than the actual number of infants.
bIncludes all malformations (major, minor, chromosomal, and not otherwise specified).
NSDB, Novartis safety database; PRIM, PRegnancy outcomes Intensive Monitoring.
Table 4. Description of anomalies observed among prospective cases.
Case no Birth type Details System organ class
Congenital anomaly major
1 Term live birth Talipes Musculoskeletal
2 Term live birth Congenital ureteric anomaly Renal
3 Term live birth Developmental hip dysplasia Musculoskeletal
(Continued)
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Case no Birth type Details System organ class
4 Term live birth Talipes; Amniotic band syndrome Musculoskeletal
5 Term live birth Congenital cardiac septal defect Cardiac
6 Term live birth Congenital cardiac septal defect; polydactyly Cardiac, 
Musculoskeletal
7 Term live birth Acrania Musculoskeletal
8 Term live birth Renal dysplasia Renal
9 Term live birth Two heart defects with resuscitated cardiac 
arrest on Day 3
Cardiac
10 Term live birth Congenital hydronephrosis, renal hypoplasia Renal
11 Term live birth Micropenis Reproductive
12 Term live birth Hydronephrosis Renal
13 Term live birth Heart disease congenital Cardiac
14 Term live birth ASD, VSD; chromosomal deletion Cardiac, Chromosomal
15 Term live birth Oesophageal atresia; ASD Gastrointestinal, 
Cardiac
16 Preterm live birth Corpus callosum agenesis, no chromosomal 
defect
Neurological
17 Preterm live birth ASD Cardiac
18 Preterm live birth Congenital hand malformation, ectopic kidney Musculoskeletal, Renal
19 Preterm live birth Congenital tibial bowing Musculoskeletal
20 Stillbirth Turner’s syndrome Chromosomal
21 TOPFA Trisomy 21 Chromosomal
22 TOPFA agenesis of corpus callosum, syndactyly; 
mesocardia
Nervous system
23 TOPFA Embryo overt spina bifida Nervous system
24 TOPFA Trisomy 21 Chromosomal
25 TOPFA Tetralogy of fallot Cardiac
Congenital anomaly NOS (structural)
26 TOPFA Chromosomal deletion (amniocentesis) Chromosomal
27 Term live birth Heart murmur NOS, mild Cardiac
28 Term live birth Abnormal liver size Hepatobiliary
Congenital anomaly minor
29 Term live birth Inguinal hernia Gastrointestinal
30 Term live birth Congenital foot malformation Musculoskeletal
31 Term live birth Patent foramen ovale Cardiac
Table 4. (continued)
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preterm live births including one with congenital 
malformation.
Discussion/conclusion
The prevalence of major congenital malforma-
tions (excluding chromosomal anomalies) of all 
three prospective data sources observed in this 
analysis was 2.7% (95% CI: 1.0; 5.9) to 4.0% 
(0.8; 11.2) in live births) and 3.2% (1.3; 6.4) to 
5.3% (1.5; 12.9) in live births, stillbirths and 
TOPFA. In the general population, the preva-
lence of major malformations varied between 
2.0% (2.0; 2.1)7 and 4.5% (4.5; 4.5)8 for live 
births, and 2.6% (2.6; 2.6)7 and 6.9% (6.6; 7.2)9 
for live births, stillbirths and TOPFA. In the 
unexposed MS population, the prevalence of 
major congenital malformations in live births 
ranged between 1.4% (0.0; 7.8)10 and 6.8% 
(2.5; 14.3; Note: Wherever the CIs were not 
available in the published sources, they were cal-
culated by Clopper–Pearson method).11 The 
prevalence of major congenital malformations 
do not appear to be significantly more prevalent 
among pregnant women exposed to fingolimod 
0.5 mg than what would be expected in the gen-
eral7–9 and unexposed MS population.10,11 There 
was a trend towards lower prevalence of major 
congenital malformations in prospectively col-
lected data from PRIM compared with the 
Registry, potentially due to the different nature 
of data collection and variation in the definition 
of prospective cases. We did not identify any 
specific patterns of birth defects supporting fin-
golimod-induced effects. Our sample size, the 
largest for fingolimod exposure during preg-
nancy to date, is adequate to detect an 80% 
increase in the prevalence of major malforma-
tions (assuming a background prevalence of 3%; 
80% power; two-sided test α = 0.05).
A total of 11 cardiac defects (including major and 
minor) were identified in 10 infants. Of those, 8 
were considered as major (7 defects in 6 live 
births and 1 defect in TOPFA) and were included 
in prevalence calculations (Table 4). The preva-
lence of major cardiac malformations in the 
NSDB was 1.5% (0.6; 3.0) in live births and 
1.6% (0.7; 3.2) in live births, stillbirths and 
TOPFA cases. In the general population, the 
prevalence varied from 0.2%12 to 1.1%13 in live 
births and from 0.8%14 to 1.1% (1.0; 1.2)15 in live 
births, stillbirths and TOPFA. Overall, major car-
diovascular anomalies reported with fingolimod 
showed a point estimate of reporting rate that is 
higher than prevalence estimates from the general 
community; however, the community prevalence 
estimates are contained within the 95% CIs, indi-
cating these are not statistically significant. Given 
the small number of cases with confirmed diagno-
sis, and confounding factors in the presentation 
of cases with congenital cardiac defects, this is not 
considered a safety signal for fingolimod at this 
point in time but will be re-evaluated as new cases 
are reported.
We also found that the proportions of miscar-
riages from the three data sources (6.6−14.7%) 
were within the range reported for the general 
population [14.2 (13.2; 15.3)16 to 20.9 (18.9; 
23.0)17] and the unexposed MS population 
[4.3% (0.1; 22.0)18 to 21.1% (13.4; 30.6)10]. A 
higher proportion of miscarriages was observed 
in PRIM compared with the Registry. This may 
be because patients in the Registry were enrolled 
later than they were reported in PRIM due to the 
informed consent process, which may have led 
to a few cases of abortions in the early first tri-
mester being missed. The same has been evi-
denced by the gestational age at the time of 
enrollment/reporting.
Table 4. (continued)
Case no Birth type Details System organ class
32 Term live birth Developmental hip dysplasia Musculoskeletal
33 Term live birth Cyst on the right kidney Renal
34 Term live birth Pelvic dilatation Renal
35 Preterm live birth Patent ductus arteriosus Cardiac
ASD, atrial septal defect; NOS, not otherwise specified; TOPFA, terminations of pregnancy due to fetal anomaly; VSD, 
ventricular septal defect.
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Data from populations of women with MS 
exposed to other MS-specific medications are 
limited. The prevalence of major congenital 
malformations observed in cases exposed to 
natalizumab ranged from 3.9% (0.8; 11.0)10 to 
7.6% (4.9; 11.1) in live births and 7.9% (5.2; 
11.4) among live births, stillbirths and elective 
terminations.19 In cases exposed to glatiramer 
acetate, prevalence was 8% (0.9; 26.0) in live 
births20 and 1.5% (0.2; 5.2) in live births, still-
births and TOPFA.11 The prevalence in cases 
exposed to interferon β was 8.3% (0.2; 38.5) in 
live births21 and ranged from 3.1% (1.2; 6.3)22 
to 14.3% (1.8; 42.8) in live births, stillbirths and 
TOPFA.21 No birth defects were observed in 
cases exposed to teriflunomide in a limited num-
ber of pregnancies.
The main limitation of this analysis is the high 
number of lost to follow-up cases in the NSDB, 
including a number of cases in PRIM, which is 
typical of voluntary postmarketing reporting sys-
tems. Furthermore, a slow enrollment rate 
restricted the amount of information available 
from the Registry. Enrollment in registries, and 
prompt reporting and follow up in surveillance 
programs are critical to the evaluation of preg-
nancy outcomes, and healthcare professionals 
who treat women of child-bearing age are urged 
to participate in this ongoing important effort. 
The current data do not warrant a change in the 
recommendation provided in the label due to rel-
atively limited numbers. However, this report will 
provide useful information for women who 
become pregnant while taking fingolimod, their 
families and healthcare professionals.
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